Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Frederick Min (NPI 1366682429)

Field	Value
Entity Type	Individual
Organization	Frederick Min
Address	2101 Medical Park Dr
City	Silver Spring
State	MD
ZIP	20902
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 3, 2009

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This provider’s Medicare billing is heavily concentrated in oncology infusions and related supportive therapies: the top three Medicare codes are J9271 ($1.1M, 35.8%), J9144 ($444.6K, 14.8%), and J0897 ($373.7K, 12.5%), and those three codes together account for 63.1% of the provider’s total Medicare revenue. The prominence of pembrolizumab (J9271) and daratumumab (J9144) points to high-volume administration of immune-oncology and myeloma-targeted agents, while denosumab (J0897) indicates routine bone-modifying therapy for cancer patients. The presence of chemotherapy administration codes (e.g., 96413 and 96417) further supports an outpatient oncology infusion service model rather than a purely consultative practice.

Revenue concentration is pronounced: Medicare is effectively the entire revenue base at $3.2M in lifetime Medicare revenue, while Medicaid billing is listed as none on file. Because there is no Medicaid activity recorded, this provider operates as a de facto Medicare-only billing entity in the available data, which has implications for payer mix, risk profile, and contracting leverage with non-Medicare payers.

Competitive standing varies by code: for flagship oncology drugs the provider is a typical to modest national participant — J9271 ranks #213 of 1841 providers nationally (88th percentile) and J9144 ranks #157 of 615 (74th percentile), both described as typical, unremarkable volume. In contrast, the provider is an outsized national participant for certain product lines: Q5118 (bevacizumab biosimilar) ranks #3 of 161 providers nationally (99th percentile; extreme outlier) and 99214 office visits rank #3320 of 479517 providers nationally (99th percentile; extreme outlier), indicating unusually high relative volumes for biosimilar bevacizumab administration and mid-level established-patient E&M visits.

Several individual codes are flagged as statistical outliers or notably above typical national volume, highlighting operational specializations. Notably above typical volumes include J0897 (rank #268 of 10057, 97th percentile), J0881 (rank #29 of 1114, 97th percentile), 96413 (rank #368 of 7514, 95th percentile), and 96417 (rank #166 of 3014, 94th percentile), while extreme outlier status appears for Q5118 (99th percentile), 99214 (99th percentile), and 96372 (99th percentile). These signals together suggest concentrated, repeatable administration patterns for both high-cost biologics and frequent in-office interventions.

Operational detail: the provider reports extremely high claim counts for some low-unit-price supportive drugs, for example J0881 shows 66.8K claims at $2 avg paid/claim for $133.5K revenue, and J0897 has 20.8K claims for $373.7K revenue. High claim volumes with modest per-claim payments are consistent with routine, recurring supportive-care treatments (e.g., erythropoiesis-stimulating agents and bone-targeted therapy) that accompany an oncology infusion practice and can drive staffing, pharmacy stocking, and workflow needs.

Clinical and visit mix reinforce a combined infusion-plus-followup practice: 99214 office visits account for $168.4K (5.6%) and 99213 accounts for $40K (1.3%) of Medicare revenue, while infusion-administration add-ons and chemotherapy administration codes (96413, 96417, 96365, 96367) also appear in the top codes. This blend of E&M and infusion codes implies the provider delivers both active treatment administration and ongoing outpatient management, which affects revenue per encounter and payer negotiation priorities.

Tenure and stability: the provider’s NPI was enumerated on 2009-03-03 (~17 years ago), indicating an established billing history and likely stable referral relationships in the market. Combined with the concentrated Medicare revenue base and no Medicaid billing, this suggests an entrenched outpatient oncology operation that may have limited exposure to Medicaid populations and related payment dynamics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

86 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	25,600	$40	$1.1M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	11,700	$40	$444.6K
J0897	Injection, denosumab, 1 mg	20,760	$20	$373.7K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	9,020	$20	$216.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,550	$110	$168.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	66,750	$1	$133.5K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,010	$30	$132.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	630	$120	$76.7K
J1437	Injection, ferric derisomaltose, 10 mg	4,400	$20	$74.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	700	$80	$58.5K

Showing 1–10 of 86

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 86 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Frederick Min — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

86 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	16	60	15,000	$40	$787.6K
J9144	16	30	11,970	$40	$493.5K
J1568	5	10	3,000	$30	$121.1K
J0897	20	340	3,600	$20	$114.4K
Q5118	1	10	3,970	$20	$101.8K
J0881	6	60	30,420	$1	$76.4K
J1437	16	50	2,800	$20	$75.1K
J3490	22	100	70	$450	$62.1K
J2506	9	30	590	$80	$55.2K
93306	483	500	290	$110	$38K

Showing 1–10 of 86

Related Providers

Other providers that share a Tax Identification Number (TIN) with Frederick Min, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Kashif Ali	MD	Hematology & Oncology Physician	$3.6M	$0
Andrew Mener	MD	Hematology & Oncology Physician	$3.5M	$0
Jason Taksey	MD	Medical Oncology Physician	$3.3M	$0
Mohit Narang	MD	Medical Oncology Physician	$3M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
Deepnarayan Tiwarri	MD	Hematology & Oncology Physician	$2.6M	$0
Amr Hegazi	MD	Hematology & Oncology Physician	$2.3M	$0
Edward Lee	MD	Medical Oncology Physician	$1.9M	$0
Ravin Garg	MD	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Frederick Min, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Capital Care, Inc	MD	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$101.9M
Cornerstone Montgomery, Inc.	MD	Community/Behavioral Health Agency	$0	$29.5M
Kidz & Family Dental Center	MD	Dental Clinic/Center	$0	$13.3M
Smile Care 4 Children, LLC	MD	Pediatric Dentistry	$0	$10.5M
C Arefi B Nasehi & Associates PC	MD	General Practice Dentistry	$0	$7M
Pediatric Associates	MD	Primary Care Clinic/Center	$0	$6.8M
Right Care Pediatrics Inc	MD	Pediatrics Physician	$0	$5.3M
Derm Associates LLC	MD	Dermatology Physician	$5.1M	$11K
Virant Diagnostics, Inc	MD	Clinical Medical Laboratory	$48.8K	$4.3M
Alan Matsumoto	MD	Rheumatology Physician	$2.2M	$0

Frederick Min — Billing Profile & Reimbursement Data

Sign up for Frederick Min — Billing Profile & Reimbursement Data policy alerts

Frederick Min — Billing Profile & Reimbursement Data

Sign up for Frederick Min — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References